Program
Teverelix DP
Also written as “Teverelix DP 180 mg”.
Its studies are mostly in Endometriosis · Prostatic Hyperplasia · Prostatic Diseases, led by Antev.
Furthest: phase 2, since Feb 24, 20263 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Antev | 33 open or running | phase 2since Feb 24, 2026 | Feb 24, 2026 | Sep 2027phase 2 · NCT07457164 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2026First study: phase 2 study in Prostatic DiseasesFirst studyNCT07457164 · 40 planned
- Jul 15, 2026Phase 2 study in Prostatic HyperplasiaNCT07733934 · 126 planned
- Aug 19, 2026Phase 2 study in EndometriosisNCT07914062 · 84 planned
Ahead
- Sep 2027Primary completion: phase 2 study in Prostatic DiseasesNCT07457164
- May 2028Primary completion: phase 2 study in Prostatic HyperplasiaNCT07733934
- Dec 2029Primary completion: phase 2 study in EndometriosisNCT07914062
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07914062Endometriosis | 2 | Not yet recruiting | Dec 2029 | 84 |
| NCT07733934Prostatic Hyperplasia | 2 | Not yet recruiting | May 2028 | 126 |
| NCT07457164Prostatic Diseases | 2 | Not yet recruiting | Sep 2027 | 40 |
How it is read
Names in the registry
- “Teverelix DP”, 5 entries
- “Teverelix DP 180 mg”, 1 entry
Conditions, from the studies’ own filings
- Endometriosis, 1 study
- Prostatic Hyperplasia, 1 study
- Prostatic Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.